AL-NCD is developed by University of California, Los Angeles.

What development phase is AL-NCD in?

AL-NCD is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

AL-NCD

University of California, Los Angeles · FDA-approved active Small molecule Quality 6/100

At a glance

Generic name	AL-NCD
Also known as	Aristada Initio
Sponsor	University of California, Los Angeles
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AL-NCD CI brief — competitive landscape report
AL-NCD updates RSS · CI watch RSS
University of California, Los Angeles portfolio CI